![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00637286 |
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
Condition | Intervention | Phase |
---|---|---|
Migraine |
Drug: Zolmitriptan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated. |
Enrollment: | 120 |
Study Start Date: | July 2004 |
Study Completion Date: | May 2005 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | D1223C00002 |
Study First Received: | February 8, 2008 |
Last Updated: | April 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00637286 History of Changes |
Health Authority: | United States: Institutional Review Board |
Zolmitriptan ZOMIG migraine headache response |
headache headache pain MIDAS HCPC |
Serotonin Agonists Neurotransmitter Agents Zolmitriptan Migraine Disorders Headache Central Nervous System Diseases |
Headache Disorders, Primary Pain Brain Diseases Serotonin Headache Disorders |
Serotonin Agonists Neurotransmitter Agents Zolmitriptan Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Central Nervous System Diseases |
Headache Disorders, Primary Brain Diseases Pharmacologic Actions Headache Disorders Serotonin Agents Migraine Disorders |